2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products

Code: 
2100

Most active institutional investors by number of deals

Investor Profile Country Deals
Pfizer Inc United States 12
Three Arch Partners United States 12
Abingworth Bioventures IV LP Venture capital fund United Kingdom 11
Alloy Ventures Inc Early-stage venture capital firm that invests in Information Technology, Life Sciences, and Cleantech companies United States 11
Bio*One Capital Pte Ltd Singapore 11
Intersouth Partners United States 11
Morgenthaler Management Partners United States 11
Oxford Bioscience Partners IV LP United States 11
RoundTable Healthcare Partners United States 11
SV Life Sciences Advisers LLP United Kingdom 11
Venture Investors LLC United States 11
Advanced Technology Ventures Venture capital firm with a focus on Information Technology, Healthcare and Cleantech United States 10
Atlas Venture United States 10
Avista Capital Holdings LP United States 10
Burrill & Co LLC Diversified global financial services firm focused on the life sciences industry United States 10
Care Capital LLC United States 10
Ferrer Freeman & Co LLC Private equity firm United States 10
Galen Partners United States 10
Sequoia Capital Venture capital firm. United States 10
Abingworth Bioventures I LP Venture capital fund United Kingdom 9

Pages

Selected funding rounds

Date Company Profile Round
Jan 2012 AssureRx Health Inc Personalized medicine company specializing in pharmacogenetics Debt
Jan 2012 Probiodrug Biopharmaceutical company focused on the development of innovative small molecule drugs. Venture
2012 Venturepharma Group Provider of an innovative specialty pharmaceutical company that operates in China. N/A
Jan 2012 QR Pharma Inc Develops drugs for the treatment of mild cognitive impairment, Alzheimer's, Parkinson's, and Down Syndrome diseases
Dec 2011 Catabasis Pharmaceuticals Inc Series A
Dec 2011 Catabasis Pharmaceuticals Inc Series A
Dec 2011 Catabasis Pharmaceuticals Inc Series A
Dec 2011 Catabasis Pharmaceuticals Inc Series A
Dec 2011 InnoPharma LLC Series A
Dec 2011 arGEN-X BV Innovation-driven biopharmaceutical company. Series B
Nov 2011 Allena Pharmaceuticals Inc Developing and Commercializing Innovative Non-systemic Oral Protein Therapeutics Series A
Nov 2011 Prolacta Bioscience Inc Series D
Nov 2011 Portola Pharmaceuticals Inc Series D
18 Oct 2011 Foundation Medicine Inc Series A
Oct 2011 Azelon Pharmaceuticals Inc Series A
Oct 2011 Azelon Pharmaceuticals Inc Series A
Sep 2011 SironRx Therapeutics Inc Develops regenerative therapies for the treatment of dermal wound repair Series A
Sep 2011 Orphazyme ApS Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases. Series A
Sep 2011 Orphazyme ApS Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases. Series A
Sep 2011 Crescendo Bioscience Inc Series C

Pages

Selected companies

Company type: 
Advanced fight against drug resistant microbes by attacking novel targets with novel drugs.
Company type: 
Biopharmaceutical company developing small molecule therapeutics that target ion channels for treatment of a variety of diseases.
Company type: 
Innovative drug discovery and development company.
Subscribe to RSS - 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products